InsidersTradesSigma
Total declarations
Companies
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Insider track record
OtherDisclosed buys
6
Disclosed sells
0
T+90 hit rate
33%
T+90 mean return
-9.8%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Innoviva, Inc.. Officer active across 2 companies, notably Entasis Therapeutics Holdings Inc.. Aggregated, 6 reports have been recorded. Breakdown: 6 buys · 0 sell. Total volume traded: €85.3m. History available since 3 May 2021. The latest transaction was filed on 8 July 2022 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Innoviva, Inc.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
11,671,662 shares@ US$2.2043.4% of flowCommon StockSEC:0001140361-22-025957:0
Canonical exit: 6 Oct 2022 (T+90)
5,385,208 shares@ US$5.008.23% mcap38.7% of flowCommon StockSEC:0001567619-22-007861:0
Canonical exit: 29 Jun 2022 (T+90)
3,614,792 shares@ US$5.0036.3% of flowCommon StockSEC:0001567619-22-003750:0
Canonical exit: 10 May 2022 (T+90)
1,212,122 shares@ US$3.307.9% of flowCommon StockSEC:0001567619-21-019063:0
Canonical exit: 27 Jan 2022 (T+90)
6,268,975 shares@ US$2.0024.7% of flowCommon StockSEC:0001567619-21-012030:0
Canonical exit: 9 Sept 2021 (T+90)
3,731,025 shares@ US$2.0014.8% of flowCommon StockSEC:0001567619-21-010772:0
Canonical exit: 1 Aug 2021 (T+90)
6 of 6 declarations
About Innoviva, Inc.
Innoviva, Inc. is a director and insider at Entasis Therapeutics Holdings Inc. and Armata Pharmaceuticals, Inc.
